Drug Profile

Mdm2-p53 binding protein inhibitor - Boehringer Ingelheim/Priaxon

Alternative Names: Mdm2-p53 antagonist - Boehringer Ingelheim/Priaxon

Latest Information Update: 24 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

24 Sep 2025 Discontinued - Phase-I for Cancer (unspecified route) (Boehringer Ingelheim pipeline, September 2025)
07 Dec 2022 Phase-I clinical trials in Cancer (unspecified route) (Boehringer Ingelheim pipeline, December 2022)
16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com